Literature DB >> 2543755

A variant of herpes simplex virus type 2 strain HG52 with a 1.5 kb deletion in RL between 0 to 0.02 and 0.81 to 0.83 map units is non-neurovirulent for mice.

M Y Taha1, G B Clements, S M Brown.   

Abstract

The virulence of a deletion variant of herpes simplex virus type 2 (HSV-2) strain HG52 has been determined by intracranial inoculation of 3-week-old BALB/c mice. The variant JH2604 has a 1.5 kb deletion within each copy of the long repeat region (RL) of the genome between 0 to 0.02 and 0.81 to 0.83 map units. JH2604 is avirulent for mice compared to the parental wild-type virus, and fails to replicate in mouse brain in vivo. Correction of the deletion by marker rescue resulted in the isolation of recombinants which gave LD50 values comparable to those of individual plaque stocks of the parental HG52. Introduction of the deletion into wild-type virus resulted in recombinants which on intracranial inoculation of mice were avirulent. The results imply that sequences within the 3 kb terminal portion of RL are required for virulence of HSV-2 strain HG52.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543755     DOI: 10.1099/0022-1317-70-3-705

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of gamma(1)34.5 transcripts and latency-associated transcripts.

Authors:  L Y Lee; P A Schaffer
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1.

Authors:  N S Markovitz; D Baunoch; B Roizman
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34.

Authors:  S M Brown; A R MacLean; E A McKie; J Harland
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models.

Authors:  R J Whitley; E R Kern; S Chatterjee; J Chou; B Roizman
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

5.  Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.

Authors:  W D Hunter; R L Martuza; F Feigenbaum; T Todo; T Mineta; T Yazaki; M Toda; J T Newsome; R C Platenberg; H J Manz; S D Rabkin
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.

Authors:  P Sundaresan; W D Hunter; R L Martuza; S D Rabkin
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Up to four distinct polypeptides are produced from the γ34.5 open reading frame of herpes simplex virus 2.

Authors:  Maria Korom; Katie L Davis; Lynda A Morrison
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

8.  Complete sequence and comparative analysis of the genome of herpes B virus (Cercopithecine herpesvirus 1) from a rhesus monkey.

Authors:  Ludmila Perelygina; Li Zhu; Holley Zurkuhlen; Ryan Mills; Mark Borodovsky; Julia K Hilliard
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Acute ascending necrotizing myelitis in Okinawa caused by herpes simplex virus type 2.

Authors:  T Iwamasa; H Yoshitake; H Sakuda; Y Kamada; M Miyazato; Y Utsumi; A Nakamura
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 10.  HSV molecular biology: general aspects of herpes simplex virus molecular biology.

Authors:  J H Subak-Sharpe; D J Dargan
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.